About Us

Vimelea Therapeutics is a pre-clinical stage drug development company. We are developing a novel platform of therapeutic small molecules that treat various inflammatory diseases. Our new class of chemical compounds were designed from an immunomodulating system in nature. Our library of small molecules provides numerous development opportunities for our therapeutic target, cutaneous lupus erythematosus (CLE), as well as a significant number of other autoimmune and chronic inflammatory disease.

Vimelea’s lead compounds modulate both myeloid and lymphoid immune cells. Both cell types play a role in CLE pathology. Our compounds are only active in unbalanced immune tissue, thus mitigating toxicity in healthy tissue. The compounds’ size and chemical structures also make for efficient manufacturing.

Founder

Dr. Darius M. Walker 

Business Advisors

Dr. Aubrey Watkins III

Mr. Steven M. Walker, MBA, MHA

Dr. Christine Copple

Mr. Brad Stewart

Mr. Jarrod Longcor, MBA, MPH, MSMS

Scientific Advisors

Prof. William Harnett

Prof. Colin Suckling